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Abstract Metastases that are resistant to conventional thera-
py are the major cause of death from cancer. In most patients,
metastasis has already occurred by the time of diagnosis.
Thus, the prevention of metastasis is unlikely to be of thera-
peutic benefit. The biological heterogeneity of metastases pre-
sents a major obstacle to treatment. However, the growth and
survival of metastases depend on interactions between tumor
cells and host homeostatic mechanisms. Targeting these inter-
actions, in addition to the tumor cells, can produce synergistic
therapeutic effects against existing metastases.
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1 Introduction
Twenty years ago, a close family member was diagnosed at the
age of 54 with colon cancer with extensive liver metastases. He
was told by his family physician that he would probably not
live another 6 months. After the successful removal of his pri-
mary tumor, he came to TheUniversity of TexasMDAnderson
Cancer Center to explore any options available to treat his liver
metastases. He was placed on a highly experimental protocol
involving direct introduction of chemotherapeutic drugs into
the liver. The metastases began to regress, and he returned to
work. With the exception of a few bad days following the
intermittent chemotherapy, his quality of life was excellent,
and he was alive to enjoy the arrival of a second grandchild.
But 3 years later, the metastases began to regrow, and when he
asked about trying a different drug regimen, he was told, “I’m
sorry, but there isn’t another option.” He returned to his home
and died there within a few months at the age of 57.
Unfortunately, 20 years later, this outcome is still not
unique. This year alone nearly 590,000 people in the USA
will die from cancer [1]. In spite of the promise of new ther-
apies targeting genes gone awry in cancer cells, the fact re-
mains that even with these more effective, less toxic ap-
proaches, patients still die from metastases that eventually
escape control. In his book, The Emperor of All Maladies,
Dr. S. Mukherjee concludes that the only way to deal with
this problem using current approaches is to ensure that drug
development stays one step ahead of the emergence of resis-
tant metastases [2]. Consequently, many recent studies are
directed toward prevention of metastasis. However, this ap-
proach is also not likely to change the outcome of cancer
because in many patients, by the time of diagnosis, metastasis
has already occurred [3]. If this were not the case, surgical
excision of primary neoplasms would be curative.
2 The metastatic process
Metastasis, the transfer of disease from one organ or part to
another not directly connected to it, remains the primary chal-
lenge in treating cancer [3, 4]. Although metastasis can occur
when primary tumors are small, in most cases, metastasis is
associated with large primary neoplasms. This is supported by
data indicating that surgical excision of small lesions is often
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curative and forms the basis for tumor, nodes, metastasis
(TNM) staging [4]. In advanced disease, metastasis has oc-
curred and lesions are established in distant organs, so
targeting early steps in the metastatic process may not be rel-
evant to therapy. Targeting metastasis must therefore distin-
guish between prevention of the process and therapy of
existing metastatic lesions.
The pathogenesis of cancer metastasis consists of a series
of sequential and interrelated steps, each of which can be rate
limiting. Failure to complete any of the steps can prevent the
formation of secondary lesions. After the initial transforma-
tion and growth of cells, vascularization must occur if a tumor
mass is to exceed 1 mm in diameter [5, 6]. The synthesis and
secretion of several proangiogenic factors by tumor and host
cells and the absence of antiangiogenic factors play a key role
in establishing a capillary network from the surrounding host
tissue [7, 8]. Next, local invasion of the host stroma occurs as a
consequence of the enhanced expression of a series of en-
zymes (e.g., collagenase) [9–11]. Once the invading cells pen-
etrate the lymphatic or vascular channels, they may grow
there, or a single cell or clumps of cells may detach and be
transported within the circulatory system. The tumor emboli
must survive immune defenses and the turbulence of the cir-
culation [3, 4]. They must then arrest in the capillary bed of
distant organs, extravasate into the organ parenchyma, and
proliferate to establish a micrometastasis. The growth of these
microscopic lesions requires the development of a vascular
supply and evasion of host immune cells [3, 4].
Only a few cells in a primary tumor are able to give rise to a
metastasis [12, 13], and tumor cells that fail to complete all of
the steps of the process are eliminated [12]. The entrance of
tumor cells into the circulation is common, and more than a
million cells per gram of primary tumor can be shed daily [14].
Circulating tumor cells have been found in the blood of many
cancer patients [15], whether their presence can predict that
metastasis will occur is still unclear [16, 17]. For example,
circulating tumor cells were found in the blood of patients with
benign colon diseases [16]. Also, the use of peritoneovenous
shunts to reduce ascites in patients with advanced ovarian can-
cer [17] allowed millions of tumor cells to enter the circulation
every 24 h. These patients rarely developed secondary lesions
[17]. Even the arrest in capillary beds of various organs does
not predict the subsequent development of metastases. Quanti-
tative experiments using radioactive-labeled melanoma cells
injected intravenously into syngeneic mice demonstrated that
only <0.1 % of the injected cells survived to produce metasta-
ses. Moreover, although the tumor cells reached all organs,
metastases developed in only a few [12]. Thus, the presence
of tumor cells in the circulation does not necessarily predict that
metastasis will occur [18].
Oncologists are well aware that metastasis is not a random
process because the pattern of metastasis produced by differ-
ent cancers is predictable [3, 4]. This conclusion was first
enunciated by Stephen Paget in 1889 when he published the
report, “Distribution of Secondary Growths in Cancer of the
Breast,” to answer the question, “What is it that decides what
organs shall suffer in a case of disseminated cancer?” [19].
Paget studied the autopsy records of 735 women with breast
cancer, questioning the discrepancy between the relative
blood supply and the frequency of metastasis in several or-
gans. He noticed the high incidence of metastasis in the lung,
liver, ovary, and specific bones and the low incidence in the
spleen. His findings contradicted the prevailing theory pro-
posed by Virchow [20] that metastasis can be explained by
the simple lodgment of tumor cell emboli in the proximal
vascular bed. Paget concluded that “remote organs cannot be
altogether passive or indifferent regarding embolism” and pro-
posed the “seed and soil” principle stating “When a plant goes
to seed, its seeds are carried in all directions; but they can only
live and grow if they fall on congenial soil.” Paget ended with
the statement, “All reasoning from statistics is liable to many
errors. But the analogy from other diseases seems to support
what these records have suggested, the dependence of the seed
upon the soil. It is our opinion that the best work in the pa-
thology of cancer is now done by those who, like Mr. Balance
andMr. Shattock, are studying the nature of the seed. They are
like scientific botanists, and he who turns over the records of
cases of cancer is only the ploughman, but his observations of
the properties of the soil may also be helpful” [19].
The “seed and soil” concept lay dormant until studies were
performed in which fragments of lung, ovary, and kidney tis-
sues were grafted into the subcutaneous space or muscle of
syngeneic mice, following which radiolabeled melanoma cells
were injected intravenously [21]. Although tumor cells reached
the vasculature of all organs, metastases developed only in the
orthotopic and grafted lungs and ovaries, but not in the
orthotopic or grafted kidneys [21], demonstrating the essential
contribution of the “soil” to this process. The “seed and soil”
hypothesis is now widely accepted [22]. The “seed” has been
renamed as the initiating cell, progenitor cell, cancer stem cell,
or metastatic cell, and the “soil” is named the stroma, host
factors, niche, or organ/tissue microenvironment. Regardless
of the terminology, it is clear that the development and survival
of metastases are dependent on the continuous interplay be-
tween tumor cells with unique metastatic properties that preex-
ists in the parental tumor [22, 23] and the microenvironment of
specific receptive organs [22–26]. Thus, the establishment of a
metastasis consists of two components: the selected metastatic
cell and the unique organ microenvironment [27, 28].
3 Strategies to prevent metastasis
A current focus of cancer research is the development of
agents that target specific genetic alterations in primary tu-
mors. This is an admirable goal because it promises to produce
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less toxic therapies tailored to individual cancers. However,
the results to date have been less beneficial than expected for a
variety of reasons [29–32]. Chief among these is the biologi-
cal heterogeneity of primary tumors and metastases [33–37]
and the plasticity of cancer cells [29–31] due to genetic insta-
bility [4, 35]. Primary neoplasms consist of multiple subpop-
ulations of cells with heterogeneity in diverse properties, such
as gene expression, karyotype, growth rate, antigenicity/im-
munogenicity, cell surface receptors, marker enzymes, sensi-
tivity to different cytotoxic drugs, invasion, and metastasis [3,
4, 34]. The cellular composition of metastases is also hetero-
geneous [38, 39], both within a single metastasis (intralesional
heterogeneity) and among different metastases (interlesional
heterogeneity) [40]. Karyotypic analyses [41–45] and single-
cell sequencing [46] demonstrated that metastases are clonal
in origin and can develop from a single surviving cell [43].
Their most daunting characteristic, however, is their increased
genetic instability [47]. This property enables new variants to
arise rapidly; those that are resistant to therapy have a selective
advantage and eventually overgrow the sensitive cells, leading
to the reemergence of metastatic disease [47].
Basing therapy on the identification of genes uniquely
expressed in a primary tumor may be of limited value because
of the heterogeneity in gene expression among different zones
within a single primary tumor [37, 40, 41], differences in gene
expression between cells in a primary tumor and those popu-
lating distant metastases, or differences among different me-
tastases arising in the same or different organs [3, 4, 48–50].
Thus, the genomic instability of tumor cells in general and the
increased genomic instability of metastatic cells in particular
may render the identification of a reliable, genetically based
target for therapy impractical. In fact, to date, targeting such
genes has not yet led to durable responses in most patients.
Whereas targeting one or several steps in the process of
metastasis may prevent the establishment of distant lesions,
in most patients, by the time of diagnosis, metastasis has al-
ready occurred [3, 4]. If this were not the case, surgical resec-
tion of primary tumors would be curative. Many current stud-
ies are attempting to inhibit various steps of the metastatic
process. For example, to enter the circulation, tumor cells
must invade the host stroma. This invasion occurs by multiple
mechanisms including the release of matrix metalloprotein-
ases. Inhibition of these enzymes can inhibit invasion and,
therefore, metastasis [10]. Embolization of circulating tumor
cells is enhanced by clumping with platelets [51–54]. Admin-
istration of aspirin to mice can prevent this interaction and
thus decrease the establishment of experimental metastasis,
but it does not reduce preexisting lesions [53, 54].
In 1971, Folkman advanced the concept of “tumor angio-
genesis: therapeutic implications” [6]. Angiogenesis, defined
as the “generation of new blood vessels,” is essential for the
growth of tumor mass beyond 1 mm in diameter [6, 7]. Inhi-
bition of angiogenesis, therefore, was envisioned to prevent
the growth of metastases beyond the 1-mm size, i.e., prevent
metastases from reaching the size that can be diagnosed in
patients and be clinically relevant.
Numerous studies directed at inhibiting angiogenesis for
therapy of metastasis have now been published [7, 55, 56].
The clinical efficacy of antiangiogenesis therapy that targets
VEGF or its receptors has been disappointing [56]. In some
experimental systems, anti-VEGF therapy actually led to ac-
celerated formation of metastasis [57]. In a recent study with
small cell lung cancer and pancreatic ductal adenocarcinoma,
the administration of low-dose cilengitide and verapamil in-
creased angiogenesis of primary tumors, but it also increased
the potency of gemcitabine, leading to reduced tumor growth
and spread [58]. These seemingly contradictory results can
readily be explained by the definition of “angiogenesis,” i.e.,
the creation of new blood vessels. In most experimental sys-
tems, the injection of tumor cells into ectopic or orthotopic
organs [26] is followed by rapid growth of tumors that re-
quires the establishment of new vasculature [59]. In clinical
trials, however, the challenge is to treat tumors that failed to
respond to conventional therapy [60]. These tumors represent
chronic lesions with a well-established blood supply [4].
Preventing the development of new vasculature is irrelevant
and unlikely to lead to regression of the lesions. Metastasis
can develop in organs, such as the lung and brain, that have
abundant capillary beds. Tumor cells can often proliferate
around existing vessels in a phenomenon labeled as vessel
co-option [61, 62]. These preexisting blood vessels negate
the need for generating new vasculature, and thus,
antiangiogenic therapy is unlikely to be effective.
Clearly, it is not enough to prevent metastases since these
mainly arise prior to surgical resection of the primary tumor.
At best, such approaches can only prevent the development of
secondary metastases, which are derived from metastatic le-
sions. Therefore, the major challenge is to treat existing me-
tastases, not prevent new metastases.
4 Targeting established metastases
The survival and growth of metastatic foci is dependent on
multiple continuous interactions with host homeostatic mech-
anisms. The conclusion by Dvorak [63] and later by Riss et al.
[64] that “cancer is a wound that does not heal” is based on the
finding that inflammatory and repair processes can aid tumor
growth and, hence, be targeted for therapy.
As stated above, targeting the existing tumor vasculature
rather than preventing angiogenesis should be a major focus
of research [47–49]. One approach to accomplish this has
been termed “the normalization of blood vessels,” defined as
the pruning of blood vessels within neoplasms and reduction
of increased vessel permeability [65–67]. The administration
of humanized IgGL monoclonal antibody (bevacizumab) with
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high affinity for isoforms of VEGF-A in combination with
chemotherapy to treat established neoplasms was proposed
to achieve this goal [68]. In other systems, administration of
bevacizumab to induce normalization of blood vessels in
xenografted ovarian carcinoma and esophageal cancer moni-
tored by increased pericytes attached to endothelial cells de-
creased the uptake of antibody by the tumors [69]. A similar
decrease in the delivery of chemotherapeutic drugs to tumors
following anti-VEGF therapy has also been reported [70].
Targeting vascular pericytes in established hypoxic tumors
increased angiopoietin-2 expression and led to increased lung
metastases. Depletion of pericytes and targeting of
angiopoietin-2 signaling restored vascular stability and de-
creased tumor growth and production of metastasis [71]. Re-
gardless of these contrasting data, the value of normalizing
tumor blood vessels for the treatment of metastases in some
organs may have beneficial results and should be tested. Inhi-
bition of angiogenesis can lead to accelerated formation of
metastasis [57] which, again, emphasizes the importance of
distinguishing between targeting angiogenesis in primary neo-
plasms and in metastases. The latter are the challenge for the
treatment of patients [55] in systems where metastases are
well established and, thus, represent the clinical reality. More-
over, in organs such as the brain and lung where vessel co-
option is common [62, 63], using antiangiogenic therapy may
not be effective.
The production of growth factors by tumor cells, and more
so by host cells, can accelerate expansion of tumors. Targeting
growth factors, such as EGF or the EGF receptors, have pro-
duced significant therapeutic effects [72, 73]. The influence of
host inflammatory cells on the growth and spread of cancer is
also well documented [74–76]. Targeting these inflammatory
changes has been shown to have additive therapeutic effects
when combined with chemotherapeutic agents that target the
tumor cells [77]. Pancreatic carcinoma is associated with
marked fibrosis and stromal microfibroblasts. This stroma has
been shown to promote the growth of pancreatic cancer [77,
78], and therefore, targeting the stroma is likely to have thera-
peutic benefits in this highly malignant disease which responds
poorly to chemotherapy directed against the tumor cells.
In some organs, activation of immune cells such as lympho-
cytes [79, 80] can produce dramatic therapeutic effects. Mac-
rophages can discriminate between normal and tumorigenic
cells [81], and activating macrophages in vivo by intravenous
injection of liposomes containing MTP-PE has been shown to
cure osteogenic sarcoma lung metastases in children [82, 83].
The diffusion distance of oxygen from capillaries within
tissues is about 150–200 μM [84, 85]. Immunohistochemical
analysis revealed that tumor cells located less than 100 μM
from a capillary in brain metastasis are viable, whereas more
distant tumor cells undergo apoptosis [59]. This study also
demonstrated that the blood-brain barrier (BBB) is intact in
and around brain metastases smaller than 0.25mm in diameter
but is leaky in larger metastases [59]. The progressive growth
of tumor cells in experimental brain metastasis and brain tu-
mors depends on the expression of VEGF/vascular permeabil-
ity factor (VPF) [86]. Transfection of human lung cancer cells
with an antisense VEGF-165 gene decreased the formation of
brain metastasis. In contrast, transfection of cells from human
squamous carcinoma of the lung with sense VEGF-121 or
sense VEGF-165 neither increased nor inhibited the formation
of brain metastasis. These results suggest that while VEGF
expression is necessary, it is not sufficient for the formation
of brain metastasis and that inhibition of VEGF presents an
important target for therapy of brain metastasis [86].
Targeting the established vasculature of metastases should
provide a susceptible target for therapy. Inhibiting phosphor-
ylation of platelet-derived growth factor receptors on endothe-
lial cells by using imatinib combined with taxol has been
reported to kill endothelial cells in vessels of multidrug-
resistant prostate cancer leading to a decrease in incidence
and size of experimental bone metastases [87]. Similarly, in-
hibition of the epidermal growth factor receptor and VEGFR
phosphorylation on tumor-associated endothelial cells can
produce apoptosis in tumor vasculature and tumor cells of
orthotopic human colon carcinoma in nude mice [88]. Induc-
tion of apoptosis in tumor-associated endothelial cells leads to
therapy of orthotopic human pancreatic carcinoma in nude
mice [89]. Macitentan, a dual endothelin receptor antagonist,
combined with taxol produced a significant therapy of
established multidrug-resistant orthotopic human ovarian car-
cinoma growing in nude mice [90]. This combination pro-
duced apoptosis of tumor-associated endothelial cells follow-
ed by apoptosis of tumor cells deprived of oxygen [90].
The organ microenvironment is conducive to the develop-
ment, progression, and survival of brain metastases. Metasta-
tic cells in the brain and primary brain tumors are resistant to
chemotherapy. Since the growth of tumor lesions in the brain
exceeding 0.25 mm in diameter is associated with expression
of VEGF/VPF [59] and leakiness of the blood-brain barrier,
the metastatic cells in the brain as well as cells in primary brain
tumors are resistant to chemotherapy [91]. A recent work from
our laboratory reported that in clinical cases of brain metasta-
ses and experimental models, tumor cells are surrounded by
activated GFAP-positive astrocytes. Astrocytes normally es-
tablish gap-channel junctions with endothelial cells and neu-
rons; however, such junctions also occur between astrocytes
and tumor cells [92, 93]. One physiological function of astro-
cytes is to protect neurons from damage by toxic substances.
However, tumor cells also benefit from this mechanism. As-
trocytes release endothelin-1 which binds to endothelin recep-
tors in tumor cells [94]. The activation of the endothelin re-
ceptors leads to increased expression of survival genes and
proteins and, hence, increased resistance to chemotherapeutic
drugs. Antagonists of the endothelin axis, combined with che-
motherapy, prevent the production of antiapoptotic proteins
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(GSTA5, Bcl2L1, TWIST1) in tumor cells and increase their
vulnerability to anticycling drugs [94].
Astrocytes have also been implicated in the establishment
and growth of melanoma brain metastasis by secretion of IL-
23, which induces neuroinflammatory changes and repair [95].
5 Conclusion
Targeted therapy requires a target. Focusing only on the tumor
cell (seed) as an approach to cancer therapy misses the oppor-
tunity to also manipulate the host microenvironment (soil) to
render it less hospitable for the growth and survival of metas-
tases. Although the metastatic cell is an elusive target because
of its genetic instability, the organ microenvironment repre-
sents a stable target that might be manipulated to the detriment
of even established metastases. Treatment of metastases
should take advantage of the dependence of metastatic tumor
cells on a receptive organ microenvironment. Simultaneously
targeting tumor cells and manipulating the organ microenvi-
ronment are more likely to produce the long-awaited therapy
of metastasis than focusing solely on the metastatic cells.
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